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SUMMARY
Schistosomiasis is a major human helminth infection endemic in developing countries. Urogenital schistosomiasis, caused
by S. haematobium, is the most prevalent human schistosome disease in sub-Saharan Africa. Currently control of
schistosome infection is by treatment of infected people with the anthelmintic drug praziquantel, but there are calls for
continued eﬀorts to develop a vaccine against the parasites. In order for successful vaccine development, it is necessary to
understand the biology and molecular characteristics of the parasite. Ultimately, there is need to understand the nature and
dynamics of the relationship between the parasite and the natural host. Thus, my studies have focused on molecular
characterization of diﬀerent parasite stages and integrating this information with quantitative approaches to investigate the
nature and development of protective immunity against schistosomes in humans. Proteomics has proved a powerful tool in
these studies allowing the proteins expressed by the parasite to be characterized at a molecular and immunological level. In
this review, the application of proteomic approaches to understanding the human-schistosome relationship as well as testing
speciﬁc hypotheses on the nature and development of schistosome-speciﬁc immune responses is discussed. The
contribution of these approaches to informing schistosome vaccine development is highlighted.
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INTRODUCTION
Schistosomiasis is a neglected tropical disease (NTD)
aﬀecting between 200–400 million people globally
(Bethony et al. 2011). The recent ﬁrst World Health
Organisation (WHO) report on NTDs cites that 90%
of the world’s schistosomiasis cases now occur in sub-
Saharan Africa (WHO, 2011). Schistosoma haemato-
bium is themost prevalent human schistosome species
in Africa and causes urogenital schistosomiasis whose
clinical symptoms include haematuria, dysuria,
hydronephrosis and calciﬁcation of the bladder.
Urogenital schistosomiasis is also associated with
bladder cancer (Parkin, 2008) and an increased risk
of HIV infection (Kjetland et al. 2006). Control is
primarily by treatment with the antihelminthic drug
praziquantel which is cheap (approximately US$
0·50/dose), eﬃcacious (cure rates >90%) and safe; it is
used in mass drug administration programmes aimed
primarily at school children. Despite all these
attributes of praziquantel, the WHO report on
NTDs notes that the goal of reaching 75% of school
age children by the end of 2010 advocated for by the
World Health Assembly (WHA) Resolution 54·19
and adopted by the WHA in 2001 was not realised
with less than 10% treatment coverage having been
achieved by 2008 (WHO, 2011). One of the problems
associated with helminth control is the need for
repeated treatment due to rapid re-infection, thus
vaccination has been suggested as an additional tool
for integrated helminth control.
Successful vaccine development requires an under-
standing of the immunological interaction (both
protective and pathological) between the host and
the parasite in addition to understanding the nature
and development of protective acquired immune
responses stimulated by the parasite. Methodologies
and technologies for characterizing immune res-
ponses to parasites have become more sophisticated
with the advent of both parasite genome sequence
(Berriman et al. 2009; Zhou et al. 2009) data and high
throughput platforms such as microarrays. Despite
these technological and scientiﬁc advances, vaccine
development for human helminth parasites has yet
to produce a single licensed vaccine product com-
pared to advances in animal helminth vaccines
(Lightowlers et al. 2003). In this current climate of
vast amounts of sequence data and rapid technologi-
cal developments, the challenge is to identify and
pose the ‘right’ biological questions and use those
tools at our disposal to answer them. One of the main
obstacles to this process is that many fundamental
questions on the nature and dynamics of protective
immune responses in human helminths remain
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unanswered. Questions such as (1) which parasite
stage stimulates a protective immune response? (2)
Against which parasite stage are protective responses
directed? (3) How do naturally acquired protective
responses diﬀer from vaccine-induced protective
immune responses? For example, natural anti-IgE
responses against the hookworm antigenAncylostoma
secreted protein (ASP-2) are protective against hook-
worm infection but vaccine-induced responses
trigger pathological responses whose clinical out-
come is urticaria (Bethony et al. 2011). (4) Why do
single antigen recombinant vaccines provide a large
percentage of protection in some helminth species
(e.g. the EG95 recombinant vaccine in Echinococcus
granulosus is 100% protective in sheep) and only very
weak protection in others (the 26 kDa GST recom-
binant Schistosoma japonicum recombinant vaccine
elicited 24% protection in mice) (Liu et al. 1995). In
addition to these questions, the applicability of
vaccine-induced protective immunity generated in
animal models to humans remains to be evaluated.
Diﬀerences in the history of infection occurring in
human and naturally infected animals which are not
reproduced in experimental studies may aﬀect the
development and type of protective immunity in
heterogeneous human populations (Wherry et al.
2003).
My own studies are concentrated on molecular
characterization of schistosome parasites and inte-
grating these studies with quantitative approaches to
investigate the nature and development of protective
immunity against schistosomes in humans. In this
review, I focus on the application of proteomic
approaches that we have used to characterize schisto-
some parasites as well as to test speciﬁc hypotheses on
the development of naturally acquired and anthel-
mintic drug altered schistosome-speciﬁc immune
responses in human populations.
CHARACTERIZATION OF SCHISTOSOME
PARASITES THROUGH COMPARATIVE
PROTEOMICS
There are similarities in immune responses stimu-
lated by diﬀerent helminth species in humans (Allen
andMaizels, 2011) which have contributed to several
shared epidemiological patterns in human popu-
lations exposed to diﬀerent helminth species such as
aggregation of infection, convex age-infection curves,
peak shifts and pre-disposition to heavy infection
(Anderson and May, 1992; Woolhouse, 1998).
However, diﬀerent helminth groups diﬀer in their
life histories and interaction with their hosts high-
lighting fundamental diﬀerences and phenotypic
plasticity within host-helminth interactions (see re-
view by Bourke et al. 2011). Thus, molecular
comparisons between diﬀerent helminth species
should highlight diﬀerences between parasites that
may be related to speciﬁc interactions with their
hosts. While genomic and transcriptomic diﬀerences
are informative for evolutionary studies as well as
giving indications on the level of genetic diﬀerences,
they do not take into account post-transcriptional
regulation of protein expression and cannot deter-
mine the degree of epitope cross-reactivity between
parasite species (Lopez, 2007). Therefore, proteomic
comparisons can give a better indication of pheno-
typic diﬀerences between diﬀerent parasites. In our
studies, we have compared the proteome of adult
Schistosoma haematobium to that of the animal
schistosome S. bovis, an important parasite of cattle,
sheep and goats. These two schistosome species have
diﬀerent mammalian deﬁnitive hosts and occupy
diﬀerent niches within the vasculature of these
hosts, and they utilise the same intermediate host
(Rollinson et al. 1997). Furthermore, hybridisation
has been reported between the two species demon-
strating their close phylogenetic relationship (Huyse
et al. 2009). Sequences of small and large nuclear
subunit ribosomal RNA genes and partial mito-
chondrial cytochrome oxidase 1 sequences indicate
a close similarity between S. haematobium and
S. bovis (Bowles et al. 1993; Webster et al. 2006).
Similarities betweenS. haematobium andS. bovis also
translate to some level of antigenic similarity leading
to a greater degree of heterologous immunity than
that observed between S. haematobium and the
other major human schistosomes, S. mansoni and
S. japonicum (Grogan et al. 1997). Therefore,
comparing these closely related schistosome species
would give an indication of any diﬀerences that may
be due to speciﬁc host-parasite interactions. The
current lack of genome sequence data for
S. haematobium and S. bovis means some proteins
present in the proteome cannot be identiﬁed if they
lack homologues in the sequenced S. mansoni
(Berriman et al. 2009) or S. japonicum genomes
(Zhou et al. 2009). In my laboratory, we conducted
proteomic comparisons using the Diﬀerence Gel
Electrophoresis (DiGE) (Alban et al. 2003). The
approach is summarized in Fig. 1. Indeed, this com-
parison showed some interesting diﬀerences, mostly
related to proteins involved in response to stress
(e.g. changes in pH, attack by reactive oxygen
metabolites and depletion of essential nutrients)
(Kaufmann, 1990a,b), Heat Shock Protein (HSP)
70 despite 91% similarity between the two species as
shown in Fig. 2A (adapted from Cook et al. 2011;
Higon et al. 2011). The biological implications of
the diﬀerence in HSP70 expression (at least 5-fold
diﬀerence) has yet to be determined. HSP70 is
expressed in cercariae and adult-stage schistosomes.
Generally HSP70 expression is induced early dur-
ing infection in parasitic organisms and plays a
critical role during adaptation to the new environ-
ment (Maresca andKobayashi, 1994). Inmost organ-
isms as well as in parasites, several genes coding for
HSP70 exist, but only some are stress-inducible. In
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schistosomes, expression of HSP70 in adults can be
induced by increasing temperature and stress
(Maresca and Kobayashi, 1994). Therefore, the
diﬀerences in HSP70 between the two schistosome
species may be related to diﬀerences in host-related
stresses. This would be consistent with results
from previous inter-species comparisons in Fasciola
trematodes where F. hepatica and F. gigantica show
diﬀerent levels of HSP70 expression (Smith et al.
2008). Furthermore, host-related diﬀerences in
HSP70 expression occur in Echinostoma species
with parasites from less permissive hosts expressing
diﬀerent levels from parasites in hosts with which
they are more compatible (Higon et al. 2008).
To further determine diﬀerences associated with
diﬀerent life histories, we compared the adult worm
proteomes of the two schistosome species to that of
another trematode, the experimental model parasite
Echinostoma caproni which does not have a tissue
phase in the mammalian host and resides in the
gastrointestinal tract (Fig. 2B). Despite the fact that
echinostomes belong to a diﬀerent genus, they
show protective immunological cross-reactivity with
parasites of the genus Schistosoma (Sirag et al. 1980).
Unsurprisingly, there are diﬀerences in the
expression levels of of both HSP70 and HSP60
whose expression was increased at least 5 fold in
S. haematobium compared to that in E. caproni.
Although this proteomic comparison provides an
important insight into the molecular features under-
lying their distinct life histories, demonstrating
diﬀerences in the E. caproni and S. haematobium
proteome alone is not enough to fully understand
phenotypic diﬀerences in the host-parasite
interactions. In this respect, we have commenced
looking at diﬀerences in immunogenicity and cross-
reactivity between the trematodes and have already
shown varying degrees of cross-reactivity, with the
greatest cross-reactivity unsurprisingly occurring
between the two schistosome parasites (Cook et al.
2011). Further studies to characterize abundantly
expressed but non-immunogenic proteins are cur-
rently underway. Such studies will be useful in
informing vaccine development for, (1) cross-species
protection (e.g. S. haematobium and S. mansoni exist
as co-infections in some areas in Africa), and (2)
determining suitable experimental models for vac-
cine evaluation prior to human clinical trials.
IDENTIFICATION OF IMMUNOGENIC
SCHISTOSOME PROTEINS IN HUMAN HOSTS
Parasite vaccine candidate discovery studies have
focused on identifying antigens that stimulate pro-
tective immune responses during natural infections
in target hosts and attempting to reproduce these
responses artiﬁcially. In order to identify candidate
antigens, it is necessary to determine which of the
parasite proteins are immunogenic. The approach
used in our studies has been to separate the parasite
proteins using 2-D electrophoresis, followed by
Western blotting with sera from populations natu-
rally exposed to schistosome infections, and thus
screen for antigens reactive with these sera (Mutapi
et al. 2005). Recognised antigens (spots on the
Western blot gel) are then matched to a Coomassie-
blue stained 2-D gel of the parasite proteome
(preparative gel) and the speciﬁc spots excised from
Fig. 1. A summary of the diﬀerence gel electrophoresis (DiGE) used to compare abundance of proteins between
diﬀerence proteomes. The proteins from each proteome are labelled with ﬂuorescent dyes (for example Cy3, Cy5, Cy2)
prior to two-dimensional electrophoresis. After the gel electrophoresis, the gel is scanned with the excitation wavelength
of each dye one after the other. Quantitative analysis is then conducted through diﬀerential in gel analysis (DIA) with
image analysis software such as DeCyder from GE Healthcare.
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Fig. 2. Diﬀerential in gel analysis (DIA) images for the comparison between schistosomes and the echinostsome
parasites showing the diﬀerent abundances of diﬀerent proteins and the corresponding histogram comparing the
abundance of each protein spot on the gel as well as the overall % similarity in the proteomes.
A) Comparing S. haematobium with S. bovis. Green spots=higher expression in S. haematobium; Red spots=higher
expression in S. bovis; Blue spots=expression levels similar in both species.
B) Comparing E. caproni with S. haematobium. Green spots=higher expression in S. haematobium; Red spots=higher
expression in E. caproni; Blue spots=expression levels similar in both species.
C) Comparing E. caproni with S. bovis. Green spots=higher expression in E. caproni; Red spots=higher expression in
S. bovis; Blue spots=expression levels similar in both species. Fig. adapted from Higon et al. 2011.
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the preparative gel, digested and subjected to tandem
mass spectrometry to obtain identiﬁcations (Mutapi
et al. 2005). This approach provides information
both on the characteristics of immunogenic parasite
antigens as well as the nature of the serological
response directed against them during a natural
infection in the human host (e.g. antibody isotype-
speciﬁc reactivities (Mutapi et al., 2011). A further
advantage is that these variations can be related to
host characteristics, including age and infection
intensity, providing a link between molecular para-
sitology and epidemiology (Mutapi et al. 2008). The
advantages of this approach over the traditional
methods of screening expression libraries with
serum samples from infected or vaccinated animals
include the ability to detect immunogenic epitopes
arising from post-translation modiﬁcations. Our
studies determining the immunogenic proteins
using the combined 2-D Western and proteomics
approach have identiﬁed more novel schistosome
antigens in a single experiment than the collective
eﬀort in the ﬁeld in the preceding 10 years demon-
strating the power of the approach, i.e. at least 71
antigens comprising diﬀerent proteins as well as
diﬀerent isoforms of the same proteins (Mutapi et al.
2005) as shown in Table 1. This study showed that
the heat shock proteins were immunogenic, consist-
ent with previous reports from other studies and also
from other parasite species (Kaufmann, 1990).
However, there is a limitation to the number of
antigens that can be identiﬁed through the gel-based
proteomic approaches. This is due to the diﬀerences
in sensitivities of the stains on the preparative gels,
solubility of parasite proteins and the Western
blotting technique. This means that some highly
immunogenic proteins seen on the Western blots
cannot be visualised on the prep gel and therefore
cannot be identiﬁed. This may also be occurring in
the case of less abundantly expressed proteins.
Advances in the protein array approaches in antigen
discovery oﬀer some promise in overcoming some
of these limitations (Driguez et al. 2010) though
integrating the two methods may give a more com-
prehensive array of parasite antigens and therefore, be
more informative.
CHARACTERIZING THE ANTIBODY SUBCLASSES
THAT RECOGNISE IMMUNOGENIC SCHISTOSOME
PROTEINS IN HUMAN HOSTS
Diﬀerent antibody subclasses have diﬀerent eﬀector
functions and several human ﬁeld studies have
focused on characterizing the dynamics of diﬀerent
antibody subclass responses to helminth parasites
(for example, Correa-Oliveira et al. 1988; Dunne
et al. 1992; Grzych et al. 1993; Quinnell et al. 1995;
Wherry et al. 2003). Therefore, some antibody
subclasses, such as IgM, have been described as a
marker of exposure to schistosome parasite antigens
(Wherry et al. 2003), IgG4 as a marker of infection
status in ﬁlarial infections (Kwan-Lim et al. 1990),
others such as schistosome and hookworm IgE as a
marker of resistance to re-infection (Hagan et al.
1991; Hagan, 1992; Hagel et al. 2003). We earlier
demonstrated that the production of some antibody
subclasses is inversely correlated; speciﬁcally, high
IgA producers did not produce high levels of IgG1
and vice versa (Wherry et al. 2003). Furthermore,
only high IgG1 and low IgA producers had little or
no infection. An inverse relationship in these two
subclasses has also been reported in a case of
idiopathic arthritis where patients deﬁcient in IgG1
had high titres of IgA (Yildiz and Kural, 2007)
suggesting that the expression of these two subclasses
is diﬀerentially regulated. What was not clear from
our immuno-epidemiological studies of the IgA and
IgG1 proﬁles was whether these antibodies were
recognizing the same antigens. Thus, the 2-D
Western blotting and proteomics approach was used
to determine the antigen recognition proﬁle of the
main antibody subclasses, IgE, IgG4, IgG1 and IgA
implicated in the expression of resistance to schisto-
some re-infection. The aim of the study was to test
the null hypothesis that the four subclasses recognise
the same parasite antigens from adult schistosomes.
This study showed that although the majority of the
parasite antigens were recognised by all four antibody
subclasses, there were some antigens whose reactivity
was restricted to only one of the subclasses (Mutapi
et al. 2011) as shown in Table 1. These diﬀerences
occurred between diﬀerent proteins as well as
between isoforms of the same protein; for example,
the two fructose 1-6-bis-phosphate aldolase isoforms
were diﬀerentially recognized by IgA and IgG1. In
general, IgG1 recognised the largest variety of
antigens followed by IgE, IgA and IgG4, respect-
ively. IgE recognized all antigens reactive with IgG4
as well as an additional four antigens, an isoform of
28-kDa GST, phosphoglycerate kinase, actin 1 and
calreticulin. IgG1 additionally recognized fatty acid–
binding protein, triose-phosphate isomerase and
HSP70, which were not recognized by IgA.
Knowing the subclasses that recognise antigens is
now an important aspect of helminth vaccine devel-
opment since people already exposed to the parasite
in endemic areas will have had some immunological
experience with the parasite or its antigens. This
could potentially lead to adverse reactions to immu-
nization, if the vaccine enhances certain types of
already existing subclass responses. The human
hookworm vaccine clinical trials evaluating the
ASP-2 vaccine had to be discontinued after Phase I
when it was shown that vaccinating people who
already had an IgE response to the protein induced
urticaria (Bethony et al. 2011). Thus, it seems
a vaccine inducing/enhancing a parasite-speciﬁc
IgE response is now less favoured compared to
that inducing an IgG1 response, making studies
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Table 1. Characterization of natural and praziquantel-induced schistosome antigen recognition proﬁles by
Zimbabwean populations exposed to S. haematobium infection. World Health Organization-listed
schistosome vaccine candidates are highlighted in bold. Un-shaded cells denote no recognition (1st quartile
range), yellow denote low intensity of recognition (2nd interquartile, orange denote medium intensity
(3rd quartile) and red denote strong intensity (4th quartile) for both. Changes in total IgG recognition
proﬁles with age and infection level and Ag recognition by diﬀerent Ab subclasses. For the Ag recognition
proﬁle by age and infection intensity the population was divided into 9 groups as follows: group 1–3 are all
aged 5–10 years and have zero (Group 1), mild (1–49 eggs/10 ml urine) (Group 2) and heavy (50+eggs/
10ml urine) (Group 3) infection levels, respectively, groups 4–6 are all aged 11–13 years and have 0 (Group
4), mild (Group 5) and heavy (Group 6) infection levels, respectively and ﬁnally groups 7–9 are all aged
14–18 years and have 0 (Group 7), mild (Group 8) and heavy (Group 9) infection levels. The middle
column (Rx) represents antigens recognised before and after treatment (yellow) and those recognised only
after anthelmintic treatment (red). Table adapted from (Mutapi et al. 2008, 2011).
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characterizing subclasses which recognise candidate
vaccine antigens an essential component of the
characterization of natural and vaccine-induced im-
mune responses.
NATURE AND DEVELOPMENT OF PARASITE –
SPECIFIC ACQUIRED IMMUNITY: EXPLAINING
THE SLOW DEVELOPMENT OF NATURALLY
ACQUIRED IMMUNE RESPONSES
Helminth infections are characterized by the slow
development of protective acquired immunity
(Anderson and May, 1992) and various explanations
have been proposed for this (Yazdanbakhsh and
Sacks, 2010). In my laboratory, we have been testing
diﬀerent hypotheses explaining this gradual devel-
opment of protective acquired immunity including
the immuno-suppressive eﬀects of helminths
(Maizels and Yazdanbakhsh, 2003) and the need for
a threshold of parasite antigens (Woolhouse and
Hagan, 1999) using a combination of quantitative
2-D Western blotting and proteomic approaches.
The quantitative studies have shown that host
immuno-suppression by parasites alone does not
reproduce the epidemiological patterns observed in
the ﬁeld (Mitchell et al. 2008). The second prop-
osition that we tested was the threshold hypothesis.
We proposed that the host immune system is eﬀective
against parasites only after exposure to a threshold
level of parasite antigens (Woolhouse and Hagan,
1999). During a natural schistosome infection,
in which adult worms can survive for an average
3–7 years (Fulford et al. 1995), it may take several
years for this threshold to be reached. To test the
hypothesis that a host must experience a threshold
amount of antigen exposure to mount a protective
response, we compared antigen-recognition patterns
(the number of antigens recognized and the intensity
of antigen recognition assayed via 2-D Western
blotting as described above) by Zimbabweans
exposed to S. haematobium infection in three
age–groups; young children (acquiring infection),
older children (in whom infection levels are peaking)
and in adults (where infection levels are declining
rapidly). Individuals within these age-groups were
further partitioned by infection level. The study
clearly demonstrated that the repertoire of antigens
recognized increased with age, peaking in the oldest
participants harbouring little or no infection
(Table 1), indicating that this increase in the
repertoire of antigens recognized was associated
with resistance to infection (Mutapi et al. 2008).
Furthermore, the intensity of antigen recognition
increased with age, peaking in the oldest participants
with the heaviest infection intensity thus indicating
a cumulative eﬀect of parasite antigens on the im-
mune responses mounted. Taken together, these
observations demonstrate that the recognition of
speciﬁc schistosome antigens, both in terms of the
diversity of antigens recognized and the intensity of
antigen recognition, increased with cumulative
exposure to parasite antigens consistent with the
need for a threshold of antigen.
DETERMINING HOW NATURALLY ACQUIRED
HUMAN ANTI-SCHISTOSOME ANTIBODY
RESPONSES ARE AFFECTED BY ANTHELMINTIC
TREATMENT
Control of schistosome infections is by treatment of
infected people with the anthelmintic drug prazi-
quantel. The drug damages the adult schistosome
tegument exposing parasite antigens including
28-kDa glutathione S-transferase, the current lead-
ing vaccine candidate antigen for schistosomiasis
(McManus and Loukas, 2008), Sm23, tubercle
glycoprotein, alkaline phosphatase and actin on the
worm surface to the host immune system (Andrews
1985; Fallon et al. 1994; Dupre et al. 1999) resulting
in the killing of the parasites. Thus, if the threshold
hypothesis holds, praziquantel treatment oﬀers a
straightforward way of testing it as it introduces a
large amount of parasite antigens at once. This
should accelerate the rate at which infected individ-
uals reach threshold levels of adult schistosome
antigens. Using the 2-D Western blotting and
proteomics approach we compared antigen recog-
nition proﬁles of the same population described
above before and after curative praziquantel treat-
ment. The results showed that praziquantel treat-
ment induced quantitative and qualitative changes
in schistosome antigen recognition patterns within
12 weeks of treatment (Mutapi et al. 2005). These
changes were not observed in untreated people.
Moreover, the antigens whose recognition was
enhanced by treatment were also those antigens
recognised naturally in untreated older people carry-
ing little or no infection (so called endemic normals
or putatively resistant people) (Mutapi et al. 2008).
The fact that anthelmintic treatment can induce
potentially protective immune responses presents a
plausible additional vaccination approach and, as
such, ﬁeld studies are currently underway evaluating
this method of inducing protective immunity to
schistosomes (Black et al. 2010a,b). The idea of
treatment-induced resistance to reinfection is neither
a novel concept nor restricted to schistosome infec-
tions. In the veterinary ﬁeld, a signiﬁcant proportion
of protozoan vaccines against some of the most
economically signiﬁcant parasites of livestock and
companion animals are based on drug-abbreviated
infections, using the so called infection and treatment
(I&T) immunisation strategy (reviewed by Meeusen
et al. 2007). Recently, a trial of the I&T protocol
was attempted in human volunteers for control of
Plasmodium falciparum, the protozoan causing the
most severe form of malaria (Roestenberg et al. 2009)
and was successful in inducing sterile immunity
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against re-infection. Even if this approach is not
eventually adapted as a vaccine strategy for schisto-
some control, it provides a vaccination model from
which general lessons can be learned for the design of
successful recombinant vaccines.Mechanistic studies
in experimental models on the eﬀect of praziquantel
treatment on the development of protective immune
responses against schistosome infections are already
shedding light on the nature of immune responses
protective against re-infection (Wilson et al. 2011).
CONCLUDING REMARKS
There has been signiﬁcant progress made in under-
standing schistosome biology through proteomic
approaches. The elegant work characterizing the
schistosome infective stages as well as secreted and
excreted products from the parasite has expanded our
knowledge of the parasite’s anatomical structure
and physiological processes (Curwen et al. 2004;
Mathieson andWilson, 2010; Mathieson et al. 2011).
Furthermore, the recent description of micro exon
genes in schistosomes and their potential for gen-
erating antigen variation represents an exciting
development in our current understanding of hel-
minth antigen diversity and how the diversity is
generated (DeMarco et al. 2010). Nonetheless, there
are still more questions to address if we are to improve
current understanding of the interaction between
helminth parasites and their natural hosts. An
understanding of the evolutionary, molecular and
mechanistic processes involved in this interaction is
essential for the development of additional interven-
tion methods against the parasites. Due to variations
arising from phenotypic diﬀerences and phenotypic
plasticity in parasites (see (Machado-Silva et al.
2011)) and heterogeneities in human populations,
studies characterizing the interaction of the whole
organisms (schistosomes and host) should be more
informative than reductionist approaches. This re-
view has focused just on a few of the proteomic
approaches that we are using to address fundamental
questions in schistosome biology and immunology.
Extension of these approaches to include assessment
of protein activities, modiﬁcations and localization
and studies of interactions of proteins in complexes
(Tyers and Mann, 2003) will enable the description
of systems-level cellular interactions between host
and parasite proteins.
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